Abstract: Articles comprising one or more calcium salts are provided. The articles can contain one or more calcium salts in an amount effective to reduce the production of TSST-1 by at least about 50% when measured by the Shake Flask Method. In certain embodiments, the one or more calcium salts can be substantially non-lethal to Staphylococcus aureus when measured by the Shake Flask Method, and/or to Lactobacillus crispatus, Lactobacillus gasseri, and/or Lactobacillus iners when measured by the Maximum Tolerated Dose Test.

Abstract: The present invention relates to a method for manufacturing an implant, in particular an intraluminal endoprosthesis, having a body containing metallic material, preferably iron. The following manufacturing method is provided for promotion of the anti-inflammatory effect of the implant: (i) providing the body of the implant; (ii) producing an at least partially closed pore structure in a portion of the structure of the implant body close to the surface; and (iii) incorporating NOX into the cavities of the pore structure. Also described is an implant manufactured in this manner.

Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, ?,?-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4.

Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.

Abstract: Anhydrous antiperspirant compositions comprising particulate antiperspirant active; capsules comprising a shear-sensitive shell which encapsulates perfume; and a carrier for the particulate antiperspirant active and capsules; wherein the capsules have a shell of cross-linked gelatin coacervate having a thickness of from 0.25 to 9 ?m and providing from 10 to 40% by weight of the capsules, a volume average particle diameter of from 25 to 70 ?m, a ratio of shell thickness to the average particle diameter in the range of from 1:5 to 1:120, and a Hysitron hardness in the range of from 1.5 MPa to 50 MPa.

Abstract: An object of the present invention is to provide an artificial nail composition which can improve adhesion between a natural nail and an artificial nail, and also can suppress exfoliation or detachment. The artificial nail composition comprises: (a) a compound having at least one radical polymerizable unsaturated double bond in the molecule, (b) an acidic phosphorus compound having at least one radical polymerizable unsaturated double bond in the molecule, and (c) a radical polymerization initiator.

Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.

Abstract: An animal attractant composition comprising 35 weight percent to 45 weight percent of a primary mineral mixture, 35 weight percent to 45 weight percent of a cobalt iodized salt, 15 weight percent to 25 weight percent of a trace mineral and Vitamins A, B and E and a method for forming an artificial animal lick that lasts no less than 3 months.

Abstract: Dietary compositions for enhancing feelings of satiety and thereby enhancing weight loss are disclosed herein. For example, dietary compositions containing a combination of beta glucan, whey protein, a natural protein extract derived from potatoes, and optionally inulin are provided.

Abstract: The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner.

Abstract: The invention relates to the use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances.

Abstract: The invention relates to the use of 5-acetyl-2,5-dimethyl-2-hydroxy-tetrahydrofuran-3-one (diacetyl dimer of formula (I)) in the form of one of its stereoisomers or in the form of a mixture consisting of or containing two, three or four of its stereoisomers (i) for imparting, intensifying and/or modifying a creamy and/or fatty sensation in the mouth, (ii) for imparting, intensifying and/or modifying a sweet, buttery, cream-like and/or creamy flavor; and/or (iii) as an aromatic and/or flavoring substance.

Abstract: Cosmetic compositions and methods with improved transfer resistance and long wear properties are disclosed. The cosmetic compositions contain a synergistic combination of at least one silicone polyurethane polymer and at least one elastomer.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.